HOME
SEARCH
RSS FEED
SUBSCRIBE
Use of beclin 1 Inhibitors, including 17-hydroxy Wortmannin, to Treat TRAIL-resistant Cancer
Case ID:
TAB-3603
Web Published:
12/6/2022
Description:
This technology includes the use of a beclin 1 inhibitor, 17-hydroxy Wortmannin, for the treatment of TRAIL-resistant colon cancer. TRAIL (TNF-related apoptosis-inducing ligand) binds to death receptors (DR4/DR5) and activates apoptosis in cancer cells. Multiple clinical trials have focused on promoting TRAIL-induced death but have had a lack of efficacy due to TRAIL resistance developing quickly in cancer cells. Recent work has found that this resistance may be mediated by a lack of activation of the apoptosis/autophagy regulator beclin 1. A compound screen was performed to find inhibitors of beclin 1 and identified 17-hydroxy Wortmannin. We found that 17-hydroxy Wortmannin can completely overcome TRAIL's resistance due to increased beclin 1 level in resistant colon cancer cells.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Patent Status
Direct Link:
https://nih.technologypublisher.com/tech?title=Use_of_beclin_1_Inhibitors%2c_ including_17-hydroxy_Wortmannin%2c_to_Treat_TRAIL-resistant_Cancer
Category(s):
Oncology
Research Materials
Therapeutics
Bookmark this page
Download as PDF
For Information, Contact:
Suryanarayana Vepa
Technology Licensing Specialist
NIH Technology Transfer
301-827-7181
sury.vepa@nih.gov
Inventors:
Sheng Dai
Wei Zheng
Keywords:
1
17-hydroxy
Autophagy
Beclin
CANCER
Cells
COLON
Increased
Inhibitions
Overcomes
Resistance
TRAIL
VCXXXX
WIXXXX
WKXXXX
Wortmannin
XEXXXX
Home
|
Search
|
RSS
|
Subscribe
© 2024. All Rights Reserved. Powered by
Inteum